BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 21197471)

  • 21. Proteasomal Degradation of the EWS-FLI1 Fusion Protein Is Regulated by a Single Lysine Residue.
    Gierisch ME; Pfistner F; Lopez-Garcia LA; Harder L; Schäfer BW; Niggli FK
    J Biol Chem; 2016 Dec; 291(52):26922-26933. PubMed ID: 27875302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
    Tang SW; Bilke S; Cao L; Murai J; Sousa FG; Yamade M; Rajapakse V; Varma S; Helman LJ; Khan J; Meltzer PS; Pommier Y
    Clin Cancer Res; 2015 Sep; 21(18):4184-93. PubMed ID: 25779942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target.
    Herrero-Martín D; Osuna D; Ordóñez JL; Sevillano V; Martins AS; Mackintosh C; Campos M; Madoz-Gúrpide J; Otero-Motta AP; Caballero G; Amaral AT; Wai DH; Braun Y; Eisenacher M; Schaefer KL; Poremba C; de Alava E
    Br J Cancer; 2009 Jul; 101(1):80-90. PubMed ID: 19491900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
    Parrish JK; McCann TS; Sechler M; Sobral LM; Ren W; Jones KL; Tan AC; Jedlicka P
    Oncotarget; 2018 Sep; 9(69):33110-33123. PubMed ID: 30237855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in
    Stolte B; Iniguez AB; Dharia NV; Robichaud AL; Conway AS; Morgan AM; Alexe G; Schauer NJ; Liu X; Bird GH; Tsherniak A; Vazquez F; Buhrlage SJ; Walensky LD; Stegmaier K
    J Exp Med; 2018 Aug; 215(8):2137-2155. PubMed ID: 30045945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.
    Zhang Y; Song J; Shi Q; Song X; Shen L; Zhou J; Shao J
    Jpn J Clin Oncol; 2019 Jul; 49(7):604-613. PubMed ID: 30927420
    [TBL] [Abstract][Full Text] [Related]  

  • 28. XI-006 induces potent p53-independent apoptosis in Ewing sarcoma.
    Pishas KI; Adwal A; Neuhaus SJ; Clayer MT; Farshid G; Staudacher AH; Callen DF
    Sci Rep; 2015 Jun; 5():11465. PubMed ID: 26095524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
    Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
    J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.
    Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O
    Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EWS/FLI1 oncogenic protein inhibits expression of the Wnt inhibitor DICKKOPF-1 gene and antagonizes beta-catenin/TCF-mediated transcription.
    Navarro D; Agra N; Pestaña A; Alonso J; González-Sancho JM
    Carcinogenesis; 2010 Mar; 31(3):394-401. PubMed ID: 20019092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas.
    Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T
    Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Promoter-Associated Noncoding RNA
    Palombo R; Frisone P; Fidaleo M; Mercatelli N; Sette C; Paronetto MP
    Cancer Res; 2019 Jul; 79(14):3570-3582. PubMed ID: 31072811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variable expression of PIK3R3 and PTEN in Ewing Sarcoma impacts oncogenic phenotypes.
    Niemeyer BF; Parrish JK; Spoelstra NS; Joyal T; Richer JK; Jedlicka P
    PLoS One; 2015; 10(1):e0116895. PubMed ID: 25603314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anatomic Origin of Osteochondrogenic Progenitors Impacts Sensitivity to EWS-FLI1-Induced Transformation.
    Pfaltzgraff ER; Apfelbaum A; Kassa AP; Song JY; Jiang W; Suhan TK; Wellik DM; Lawlor ER
    Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30845695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation on the Genomic Characterization of Uterine Sarcoma for rAd-
    Xia Y; Wang L; Ma X; Li X
    Hum Gene Ther; 2020 Aug; 31(15-16):881-890. PubMed ID: 32013587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EWS/FLI1 Target Genes and Therapeutic Opportunities in Ewing Sarcoma.
    Cidre-Aranaz F; Alonso J
    Front Oncol; 2015; 5():162. PubMed ID: 26258070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IGF-1R/MDM2 relationship confers enhanced sensitivity to RITA in Ewing sarcoma cells.
    Di Conza G; Buttarelli M; Monti O; Pellegrino M; Mancini F; Pontecorvi A; Scotlandi K; Moretti F
    Mol Cancer Ther; 2012 Jun; 11(6):1247-56. PubMed ID: 22461661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
    Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
    Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth.
    Carrillo J; García-Aragoncillo E; Azorín D; Agra N; Sastre A; González-Mediero I; García-Miguel P; Pestaña A; Gallego S; Segura D; Alonso J
    Clin Cancer Res; 2007 Apr; 13(8):2429-40. PubMed ID: 17438102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.